15 results
Thumbnail

D2.165 - Geographic Disparities in Air Pollution and Th2-Mediated Airway Inflammation in Pediatric Asthma: A Cross-Sectional Study from Mexico City

Thumbnail

D2.167 - Impact of body mass index on oscillometry parameters in children with respiratory symptoms

Thumbnail

D2.168 - Impact of type two inflammation inflamation suppression on polyp burden in patients with nasal polyposis and concomitant asthma a comparative evaluation of biologic therapies

Thumbnail

D2.171 - Clinical and demographic characteristics associated with a classification as difficult-to-treat asthma: data from the EPI-ASTHMA study

Thumbnail

D2.172 - Effectiveness of Mepolizumab in patients with severe asthma and allergic rhinitis: Real-World Evidence from the TYREX Study

Thumbnail

D2.173 - Real-World Evidence From the TYREX Study on the effectiveness of Mepolizumab in patients with severe asthma and clinically relevant aeroallergen sensitization

Thumbnail

D2.174 - Association Between Environmental Conditions and Mold Sensitization in Children with Allergic Rhinitis and Asthma

Thumbnail

D2.175 - Five-Year Real-World Outcomes of Mepolizumab Treatment in Severe Eosinophilic Asthma

Thumbnail

D2.176 - Comparison of different treatment strategies for allergic rhinitis in children and their impact on bronchial asthma

Thumbnail

D2.179 - Chronic cough triggered by industrialised milk and wheat products

Thumbnail

D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region

Thumbnail

D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor

Thumbnail

D3.155 - Th2–Th17 immune shift following dupilumab therapy

Thumbnail

D3.160 - Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry

Thumbnail

D3.164 - Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma